By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Nektar Therapeutics (AL) 

490 Discovery Drive

Huntsville  Alabama  35806  U.S.A.
Phone: 256-533-4201 Fax: 256-533-4805


SEARCH JOBS
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its proprietary polymer conjugation technology platform. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas.

In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for Nektar's oral NKTR-118 development program to treat opioid-induced constipation and its NKTR-119 development program for the treatment of pain without constipation side effects. The company has additional pain compounds in preclinical studies, including a new opioid compound scheduled to enter clinical development in 2011.

In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors. Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.


Key Statistics


Email: nektarAL@nektar.com
Ownership: Public

Web Site: Nektar Therapeutics (AL)
Employees:
Symbol: NKTR
 



Industry
Pharmaceutical






Company News
Nektar Therapeutics (AL) (NKTR) Release: Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at American Association for Cancer Research Annual Meeting 2013 4/8/2013 6:13:26 AM
Nektar Therapeutics (AL) (NKTR)'s NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting 6/6/2011 11:20:58 AM
Nektar Therapeutics (AL) (NKTR) Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 American Society of Clinical Oncology Annual Meeting 5/19/2011 10:55:10 AM
FDA Grants Orphan Drug Designation For Nektar Therapeutics (AL) (NKTR)'s Investigational Drug (NKTR) 4/21/2011 7:34:20 AM
Nektar Therapeutics (AL) (NKTR) Prices Public Offering of Common Stock 1/19/2011 7:07:26 AM
Nektar Therapeutics (NKTR) Announces Two Preclinical Data Presentations at Society for Neuroscience 40th Annual Meeting: Neuroscience 2010 11/15/2010 6:37:20 AM
Nektar Therapeutics (NKTR) Reports Third Quarter 2010 Financial Results 11/5/2010 7:08:49 AM
Nektar Therapeutics (NKTR) To Supply Polymer To Amgen (AMGN), Nektar Will Receive $50 Million 11/2/2010 6:25:29 AM
Nektar Therapeutics (NKTR) to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets 10/29/2010 9:46:52 AM
Nektar Therapeutics (NKTR) To Present at the UBS 2010 Global Life Sciences Conference 9/20/2010 8:30:30 AM
123456789
//-->